bevacizumab, erlotinib

DRUG4 trials

Sponsors

Kansai Medical University, GERCOR - Multidisciplinary Oncology Cooperative Group, Swiss Cancer Institute, Lund University Hospital

Conditions

Colorectal CancerLung CancerNon Small Cell Lung Cancer

Phase 2

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

CompletedNCT01116219

Swiss Cancer InstituteLung Cancer

Start: 2010-06-30End: 2016-05-31Target: 149Updated: 2019-05-15

Phase II Trial of Erlotinib Plus Bevacizumab for Patients with Advanced Non-Small-Cell Lung Cancer Who harboring EGFR mutation.

RecruitingJPRN-UMIN000005934

Kansai Medical UniversityNon Small Cell Lung Cancer

Start: 2011-07-01Target: 24Updated: 2026-06-29

Phase 3

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

CompletedNCT00265824

GERCOR - Multidisciplinary Oncology Cooperative GroupColorectal Cancer

Start: 2005-05-31Updated: 2015-12-11

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

CompletedNCT01229813

Lund University HospitalColorectal Cancer

Start: 2010-10-31End: 2013-12-31Updated: 2015-04-13

Related Papers

Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.

Journal of Clinical Oncology2018-02-012 citations

Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.

Journal of Clinical Oncology2016-05-20

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

2015-10-2280 citations

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.

2015-10-1945 citations

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

Journal of Clinical Oncology2015-01-204 citations

Maintenance Therapy with ERL and BEV Prolongs Survival in Unresectable mCRC

MD Conference Express2014-11-01